Nucleoside/nucleotide drugs tend to have safety issues. If they didn’t, every company would have one that works well. Efficacy as a polymerase (or reverse-transcriptase) chain blocker is relatively easy to engineer, and these compounds are among the simplest small-molecule drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”